Amyloid Against Amyloid: Dimeric Amyloid Fragment Ameliorates Cognitive Impairments by Direct Clearance of Oligomers and Plaques

  • Hee Yang Lee
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea
  • Seungyeop Baek
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea
  • Minhae Cha
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea
  • Seung‐Hoon Yang
    Department of Medical Biotechnology Dongguk University Jung-gu Seoul 04620 South Korea
  • Illhwan Cho
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea
  • Heewon Shin
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea
  • Sejin Lee
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea
  • Hye Yun Kim
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea
  • Songmin Lee
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea
  • Jisu Shin
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea
  • Donghee Lee
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea
  • Kyeonghwan Kim
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea
  • InWook Park
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea
  • Soljee Yoon
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea
  • Jiyoon Kim
    Brain Science Institute Korea Institute of Science and Technology Seongbuk-gu Seoul 02792 South Korea
  • Seong Jeong Park
    Amyloid Solution Bundang-gu Seongnam-si Gyeonggi-do 13486 South Korea
  • Seong Muk Kim
    Amyloid Solution Bundang-gu Seongnam-si Gyeonggi-do 13486 South Korea
  • Ko Eun Kim
    Amyloid Solution Bundang-gu Seongnam-si Gyeonggi-do 13486 South Korea
  • Hye Ju Kim
    Amyloid Solution Bundang-gu Seongnam-si Gyeonggi-do 13486 South Korea
  • Min‐Seok Oh
    Advanced Analysis and data Center Korea Institute of Science and Technology Seongbuk-gu Seoul 02792 South Korea
  • Gwan‐Ho Lee
    Advanced Analysis and data Center Korea Institute of Science and Technology Seongbuk-gu Seoul 02792 South Korea
  • Byung‐Yong Yu
    Advanced Analysis and data Center Korea Institute of Science and Technology Seongbuk-gu Seoul 02792 South Korea
  • Priyadharshini Kannan
    Department of Biochemical Engineering Gangneung-Wonju National University Gangneung 25457 South Korea
  • Keunwan Park
    Natural Product Informatics Research Center Korea Institute of Science and Technology Gangwon-do 25451 South Korea
  • YoungSoo Kim
    Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences Yonsei University Yeonsu-gu Incheon 21983 South Korea

この論文をさがす

説明

<jats:title>Abstract</jats:title><jats:p>Amyloid‐β (Aβ) in the form of neurotoxic aggregates is regarded as the main pathological initiator and key therapeutic target of Alzheimer's disease. However, anti‐Aβ drug development has been impeded by the lack of a target needed for structure‐based drug design and low permeability of the blood–brain barrier (BBB). An attractive therapeutic strategy is the development of amyloid‐based anti‐Aβ peptidomimetics that exploit the self‐assembling nature of Aβ and penetrate the BBB. Herein, we designed a dimeric peptide drug candidate based on the N‐terminal fragment of Aβ, DAB, found to cross the BBB and solubilize Aβ oligomers and fibrils. Administration of DAB reduced amyloid burden in 5XFAD mice, and downregulated neuroinflammation and prevented memory impairment in the Y‐maze test. Peptide mapping assays and molecular docking studies were utilized to elucidate DAB‐Aβ interaction. To further understand the active regions of DAB, we assessed the dissociative activity of DAB with sequence modifications.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ